{"title": "Taiwan Liposome PhI/II trial on acupuncture-type arthritis candidate fully enrolled", "author": "EJ Lane", "url": "https://www.fiercepharma.com/pharma-asia/taiwan-liposome-phi-ii-trial-acupuncture-type-arthritis-candidate-fully-enrolled", "hostname": "fiercepharma.com", "description": "Taiwan Liposome has achieved full enrollment for its 12-week Phase I/II candidate to treat arthritis, TLC599, a therapy administered akin to acupuncture through a microneedle that enables it to pen | Taiwan Liposome has achieved full enrollment for its 12-week Phase I/II candidate to treat arthritis, TLC599, a therapy administered akin to acupuncture through a microneedle that enables it to penetrate small joints.", "sitename": "FiercePharma", "date": "2016-06-24", "cleaned_text": "Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Subscribe Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us "}